ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VMD vs NIVF // EV/EBITDA & P/E VALUATION

Viemed Healthcare Inc. (NASDAQ) VS. NewGenIvf Group Limited (Class A) (NASDAQ) • 15-METRIC TALLY: VMD 7 — NIVF 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. NIVF) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VMD NIVF SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 57.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 13.00% -32.80% +45.80 VMD /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 6.6x — — TIE /valuation <GO>
Free Cash Flow Yield 3.15% — — TIE /fcf-yield <GO>
Operating Margin 8.50% -60.00% +68.50 VMD /operating-margins <GO>
Net Profit Margin 5.70% 68.00% -62.30 NIVF /net-margins <GO>
Revenue Growth (YoY) 20.50% -13.00% +33.50 VMD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.59 0.63 +5.96 VMD /balance-sheet <GO>
Piotroski F-Score Quality 9/9 3/9 +6.00 VMD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.1 22.5 +30.60 VMD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 20.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $379.0M $11.3M $367.7M VMD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VMD REV NIVF REV VMD GROSS % NIVF GROSS % VMD FCF NIVF FCF
FY 2025 $270.3M $4.7M 57.5% 20.2% $11.9M -$11.1M
FY 2024 $224.3M $5.4M 59.4% 33.6% $1.3M -$8.3M
FY 2023 $183.0M $5.1M — — $45.2M -$1.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
NIVF // BETA —